Johnson & Johnson has unveiled a proposed settlement valued at up to $5.5 billion in an effort to bring an end to one of the largest and longest-running product liability disputes in the company’s history. The agreement is designed to resolve approximately 69,000 lawsuits alleging that the company’s talc-based baby powder and other products contributed to ovarian cancer.
The healthcare giant emphasized that the proposed deal does not represent an admission of wrongdoing. Instead, it says the settlement is intended to provide certainty after years of litigation that has consumed significant legal and financial resources while allowing the company to focus on its core healthcare business.
Settlement Hinges on Broad Claimant Support
Before the agreement can take effect, legal firms representing at least 95% of the remaining ovarian cancer claimants in state and federal courts must approve the proposal. Johnson & Johnson said the settlement would cover nearly all outstanding talc-related ovarian cancer claims if the required participation threshold is reached.
The company plans to make payments over several years, including up to $3 billion during the initial payment period, with no additional payments scheduled before 2028. The approval process is expected to take months as participating law firms and claimants review the terms.
Company Maintains Products Were Safe
Johnson & Johnson has consistently argued that scientific evidence does not support claims that its talc-based products caused ovarian cancer. Erik Haas, the company’s vice president of litigation, described the allegations as “meritless” and said the business remained confident it would ultimately prevail if the cases continued through trial.
Haas said resolving the litigation would allow the company to move beyond the dispute and continue concentrating on developing medicines and medical technologies.
Although the company has stood by the safety of its talc products, it stopped selling talc-based Johnson’s Baby Powder in the United States in 2020 and replaced it with a cornstarch-based version. The transition was later expanded globally.
More Than a Decade of Legal Battles
The talc litigation has been underway for well over a decade, with thousands of women alleging that prolonged use of Johnson & Johnson’s talc products caused ovarian cancer. The company has repeatedly disputed those claims and has won many individual cases while also facing substantial jury verdicts in others.
Johnson & Johnson previously attempted several times to resolve the claims through bankruptcy proceedings involving a subsidiary, but courts rejected those efforts, allowing the lawsuits to continue in the traditional court system.
Recent Court Developments Added Momentum
The proposed settlement follows recent developments in federal court that cast doubt on whether plaintiffs’ expert testimony could establish that talc specifically caused individual cases of ovarian cancer. While those rulings did not dismiss the litigation, they increased uncertainty for both sides as the lawsuits moved closer to trial.
Those legal developments appear to have created an opportunity for renewed settlement negotiations after years of unsuccessful attempts to reach a comprehensive resolution.
What Happens Next
The proposed agreement is not yet final. It will move forward only if the required percentage of claimants agrees to participate. If approved, the settlement would resolve nearly all existing ovarian cancer lawsuits related to Johnson & Johnson’s talc products, though it would not apply to future claims.
For Johnson & Johnson, securing broad support for the settlement could finally close a chapter that has affected the company’s reputation and generated years of legal uncertainty. For thousands of plaintiffs, the agreement represents a potential end to a lengthy court battle that has shaped one of the most closely watched product liability cases in the healthcare industry.
